NRX Pharmaceuticals annual r&d spending
2020
2021
2022
2023
2024
2025
NRX Pharmaceuticals R&D Spending Growth & History (NRXP)
NRX Pharmaceuticals's r&d spending was $3.8M for fiscal 2025.
View full NRX Pharmaceuticals company overviewNRX Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.8M | −$2.4M | −39.07% |
| 2024 | 2024-12-31 | $6.2M | −$7.2M | −53.64% |
| 2023 | 2023-12-31 | $13.4M | −$3.7M | −21.47% |
| 2022 | 2022-12-31 | $17.0M | −$3.2M | −15.95% |
| 2021 | 2021-12-31 | $20.3M | $9.6M | +90.65% |
| 2020 | 2020-12-31 | $10.6M | — | — |
NRX Pharmaceuticals quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.1M | $1.1M | +114.39% |
| Q1 2026 | 2026-03-31 | $1.3M | $505,000 | +62.81% |
| Q4 2025 | 2025-12-31 | $557,000 | −$479,000 | −46.24% |
| Q3 2025 | 2025-09-30 | $1.4M | $818,000 | +133.88% |
| Q2 2025 | 2025-06-30 | $987,000 | −$1.8M | −64.80% |
| Q1 2025 | 2025-03-31 | $804,000 | −$944,000 | −54.00% |
| Q4 2024 | 2024-12-31 | $1.0M | −$4.3M | −80.74% |
| Q3 2024 | 2024-09-30 | $611,000 | −$2.7M | −81.56% |
| Q2 2024 | 2024-06-30 | $2.8M | −$1.1M | −27.60% |
| Q1 2024 | 2024-03-31 | $1.7M | $944,000 | +117.41% |
| Q4 2023 | 2023-12-31 | $5.4M | $923,000 | +20.71% |
| Q3 2023 | 2023-09-30 | $3.3M | −$815,000 | −19.74% |
| Q2 2023 | 2023-06-30 | $3.9M | $915,000 | +30.93% |
| Q1 2023 | 2023-03-31 | $804,000 | −$4.7M | −85.34% |
| Q4 2022 | 2022-12-31 | $4.5M | −$2.0M | −30.50% |
| Q3 2022 | 2022-09-30 | $4.1M | −$2.1M | −34.21% |
| Q2 2022 | 2022-06-30 | $3.0M | −$1.7M | −36.51% |
| Q1 2022 | 2022-03-31 | $5.5M | $2.6M | +88.48% |
| Q4 2021 | 2021-12-31 | $6.4M | — | — |
| Q3 2021 | 2021-09-30 | $6.3M | $1.9M | +44.89% |
| Q2 2021 | 2021-06-30 | $4.7M | $3.3M | +235.09% |
| Q1 2021 | 2021-03-31 | $2.9M | — | — |
| Q3 2020 | 2020-09-30 | $4.3M | — | — |
| Q2 2020 | 2020-06-30 | $1.4M | — | — |
NRX Pharmaceuticals r&d spending trends
Over the last five fiscal years, NRX Pharmaceuticals's r&d spending decreased from $10.6M to $3.8M, a change of −$6.8M. The latest reported quarter, Q2 2026, shows $2.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NRX Pharmaceuticals source filings ↗